Delving into the Latest Updates on JY-231 with Synapse

Overview

Basic Info

Drug Type

Gene therapy

Synonyms

JY 231, JY231

Target

CD19

Mechanism

CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Cell replacements

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesNeoplasms+ [1]

Active Indication

Systemic Lupus ErythematosusRefractory B Acute Lymphoblastic LeukemiaCD19 positive B-Cell Lymphoma

Inactive Indication-

Originator Organization

Guangdong Provincial People's Hospital

Active Organization

920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaGuangdong Provincial People's Hospital

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

his study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory neurologic immune disorders. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed/refractory neurologic immune disorders.

Start Date08 Feb 2025

Sponsor / Collaborator

Tongji Hospital Tongji Medical College of HUST

NCT06689917

/ Not yet recruitingNot ApplicableIIT

An Early Exploratory Clinical Study of the Safety, Tolerability and Preliminary Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma/Leukaemia

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma / leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma / leukemia.

Start Date01 Dec 2024

Sponsor / Collaborator

Tongji Hospital Tongji Medical College of HUST

NCT06675422

/ RecruitingPhase 1/2IIT

JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE) - A Safety, Tolerability, and Efficacy Study

Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of active systemic lupus erythematosus (SLE)

Start Date09 Oct 2024

Sponsor / Collaborator

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

100 Clinical Results associated with JY-231

Login to view more data

100 Translational Medicine associated with JY-231

Login to view more data

100 Patents (Medical) associated with JY-231

Login to view more data

100 Deals associated with JY-231

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Systemic Lupus Erythematosus	Phase 2	CN	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China	09 Oct 2024
Refractory B Acute Lymphoblastic Leukemia	Phase 1	CN	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China	20 Jun 2024
CD19 positive B-Cell Lymphoma	Phase 1	CN	Guangdong Provincial People's Hospital	18 Aug 2023